Literature DB >> 16483862

Pathophysiology of overactive bladder.

Franklin M Chu1, Roger Dmochowski.   

Abstract

Overactive bladder (OAB) is a complex of symptoms frequently encountered in the primary care setting. Impediments to optimal management of OAB include inaccurate perceptions on the part of patients and primary care providers, e.g., that the symptoms of OAB represent a natural progression of aging and are beyond the scope of treatment or that diagnosis and treatment are specialist concerns. Complicating the physician's task is the reluctance of many patients to initiate discussion of their OAB symptoms and the fact that patients often develop disruptive coping strategies rather than seek medical treatment, possibly because of a belief that OAB is a normal part of aging rather than an actual medical condition. In most cases, OAB may be managed quite well by the primary care physician who has an understanding of the pathophysiology of OAB. This article reviews normal bladder function and then explores pathophysiologic changes that likely cause the symptoms of OAB.

Entities:  

Mesh:

Year:  2006        PMID: 16483862     DOI: 10.1016/j.amjmed.2005.12.010

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  25 in total

Review 1.  Pathophysiology of overactive bladder.

Authors:  Mai A Banakhar; Tariq F Al-Shaiji; Magdy M Hassouna
Journal:  Int Urogynecol J       Date:  2012-02-07       Impact factor: 2.894

2.  Genetic susceptibility to urinary incontinence: implication of polymorphisms of androgen and oestrogen pathways.

Authors:  J N Cornu; B Merlet; O Cussenot; G Cancel-Tassin; C Ciofu; G Amarenco; F Haab
Journal:  World J Urol       Date:  2010-07-14       Impact factor: 4.226

Review 3.  Updates of underactive bladder: a review of the recent literature.

Authors:  Xing Li; Limin Liao
Journal:  Int Urol Nephrol       Date:  2016-03-01       Impact factor: 2.370

4.  [Prediction of overactive bladder treatment outcome by using long-term urodynamics].

Authors:  S Wille; D Tenholte; O A Cornely; N Muthen; U-H Engelmann; J Mehner; O Eminaga; J Herden; P Schumacher; J Paas
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

Review 5.  Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.

Authors:  Michael B Chancellor; David R Staskin; Gary G Kay; Bobby W Sandage; Michael G Oefelein; Jack W Tsao
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

6.  Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women.

Authors:  Raquel M Arruda; Rodrigo A Castro; Gabriela C Sousa; Marair G F Sartori; Edmund C Baracat; Manoel J B C Girão
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-03-11

7.  Women With Overactive Bladder Exhibit More Unhealthy Toileting Behaviors: A Cross-sectional Study.

Authors:  Adam M Daily; Casey G Kowalik; Sophia D Delpe; Melissa R Kaufman; Roger R Dmochowski; William Stuart Reynolds
Journal:  Urology       Date:  2019-09-06       Impact factor: 2.649

Review 8.  Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.

Authors:  Michael B Chancellor; Clare J Fowler; Apostolos Apostolidis; William C de Groat; Christopher P Smith; George T Somogyi; K Roger Aoki
Journal:  Nat Clin Pract Urol       Date:  2008-05-06

Review 9.  Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review.

Authors:  S Rachaneni; P Arya; P Latthe
Journal:  Int Urogynecol J       Date:  2013-05-07       Impact factor: 2.894

10.  ADX71441, a novel, potent and selective positive allosteric modulator of the GABA(B) receptor, shows efficacy in rodent models of overactive bladder.

Authors:  M Kalinichev; S Palea; H Haddouk; I Royer-Urios; V Guilloteau; P Lluel; M Schneider; M Saporito; S Poli
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.